Announcements Trials
Browse Landscape

Phase

Phase 2 7Phase 3 3Phase 1 2Phase 4 1Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Multiple Myeloma 6Carcinoma, Hepatocellular 2Uveal Melanoma 1Prostatic Neoplasms 1Plasmacytoma 1Neoplasms, Plasma Cell 1Neoplasms 1Melanoma 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1Immunoglobulin Light-chain Amyloidosis 1Carcinoma, Renal Cell 1Amyloidosis 1

Interventions

pembrolizumab 44Nivolumab 29Gemcitabine 28Paclitaxel 19Cisplatin 18Ipilimumab 15Carboplatin 14Cyclophosphamide 13Capecitabine 12Dexamethasone 10Bevacizumab 10cemiplimab 9Irinotecan 9Docetaxel 9Albumin-Bound Paclitaxel 9130-nm albumin-bound paclitaxel 9spartalizumab 8Pemetrexed 8Sorafenib 7Rituximab 7Cetuximab 7fludarabine 6Temozolomide 6Taxes 6Radiotherapy 6Leucovorin 6Fluorouracil 6Azacitidine 6Ascorbic Acid 6lenvatinib 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Neoplasms × Thalidomide × Clear all
NCT00277017 2011-09-27

Combination Therapy With 5-Fluorouracil, Interferon-an Interleukin-2, & Thalidomide for Metastatic, Advanced or Recurrent Renal Cell Carcinoma

New Mexico Cancer Research Alliance

Phase 1/2 Completed
15 enrolled
Genitourinary

Carcinoma, Renal Cell, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡